Randomized comparison between <scp>KTd</scp> and <scp>KRd</scp> induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma

Published:2024-02-29 Issue:5 Volume:99 Page:1008-1011
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Ludwig Heinz¹^ORCID,Melchardt Thomas²,Sormann Siegfried³,Schreder Martin⁴,Andel Johannes⁵,Hartmann Bernd⁶,Tinchon Christoph⁷,Zojer Niklas⁴,Gunsilius Eberhard⁸,Podar Klaus⁹¹⁰,Egle Alexander²^ORCID,Willenbacher Wolfgang⁸¹¹,Wöll Ewald¹²,Ruckser Reinhard¹³,Bozic Boris¹³,Krauth Maria‐Theresa¹⁴,Petzer Andreas¹⁵,Schmitt Clemens¹⁶,Machherndl‐Spandl Sigrid¹⁷,Agis Hermine¹⁸^ORCID,Fillitz Michael¹⁹,Wang Song‐Yau²⁰,Zabernigg August²¹,Knop Stefan²²,Paiva Bruno²³,Greil Richard²

Affiliation:

1. Department of Medicine I, Clinic Ottakring Wilhelminen Cancer Research Institute Vienna Austria

2. Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI‐LIMCR) Paracelsus Medical University, Cancer Cluster Salzburg Salzburg Austria

3. Department of Hematology University Clinic for Internal Medicine Graz Austria

4. Department of Medicine I Clinic Ottakring Vienna Austria

5. Department of Internal Medicine II Pyhrn‐Eisenwurzen Klinikum Steyr Steyr Austria

6. Department of Internal Medicine II LKH Rankweil Rankweil Austria

7. Department for Hematology, Oncology and Palliative Care LKH Hochsteiermark, Standort Leoben Standort Leoben Austria

8. Department of Internal Medicine V Medical University Innsbruck Innsbruck Austria

9. Department of Internal Medicine II University Hospital Krems Krems an der Donau Austria

10. Molecular Oncology and Hematology Unit Karl Landsteiner University of Health Sciences Krems an der Donau Austria

11. syndena GmbH, Connect to Cure Innsbruck Austria

12. Department of Internal Medicine St. Vinzenz Krankenhaus Zams Zams Austria

13. Department of Medicine II Clinic Donaustadt Vienna Austria

14. University Clinic for Internal Medicine I, AKH Medical University of Vienna Vienna Austria

15. Department of Internal Medicine I BHS Linz Linz Austria

16. Clinic for Internal Medicine 3 Kepler University Clinic Linz Linz Austria

17. Department of Internal Medicine I Elisabethinen Linz Austria

18. Department of Internal Medicine I, Division of Oncology Medical University Vienna Vienna Austria

19. Department of Internal Medicine Hanusch Krankenhaus Vienna Austria

20. Medical Clinic and Policlinic I University Clinic Leipzig Leipzig Germany

21. Department of Internal Medicine Kufstein County Hospital Kufstein Austria

22. Klinik für Innere Medizin 5 Schwerpunkt Onkologie/Hämatologie, Klinikum Nürnberg Nord Nürnberg Germany

23. Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA) CCUN, IDISNA Pamplona Spain

Funder

Amgen

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27280

Reference6 articles.

1. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect

2. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

3. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

4. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

5. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma